Difference between revisions of "Hematopoetic progenitor cells, cord blood (Hemacord)"
m (Text replace - "package insert<ref name="insert"></ref>." to "prescribing information.<ref name="insert"></ref>") |
m |
||
| Line 12: | Line 12: | ||
==References== | ==References== | ||
<references/> | <references/> | ||
| + | |||
| + | [[Category:Drug index]] | ||
| + | [[Category:Cellular therapy]] | ||
Revision as of 20:03, 20 July 2017
FDA approved 11/10/2011
General information
Class/mechanism: Hematopoietic stem/progenitor cells isolated from cord blood; hematopoetic progenitor cells, cord blood (HPC-C) migrate to the bone marrow, engraft, divide, and produce mature blood cells. For use in unrelated donor hematopoietic progenitor cell transplantation.[1][2]
Route: IV
Extravasation: No information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Patient drug information
No information available.